Bristol Myers Squibb (BMS) has partnered with Microsoft to advance the early detection of lung cancer using artificial intelligence (AI).[4] The goal of the partnership is the development of AI technology to identify patients at high risk of lung cancer.[1][4] The collaboration was announced on January 20, 2026.[4] A related study of 525,526 patients in the Netherlands identified 2,386 cases of lung cancer (0.5 percent).[1] The algorithm selected patients with a risk almost 10 times higher than in the general population.[1] It would allow 1,480 patients (62 percent) to be referred for specialist examination four months earlier than in standard care.[1] The system works on existing medical records and accelerates the identification of the risk group.[1]